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ABSTRACT
Serious urinary tract infections (UTIs) and acute bacterial prostatitis in adults cause signiﬁcant
morbidity and economic burden. Chronic bacterial prostatitis is a rather rare condition seen in urological
practice, however, in certain occasions difﬁcult to treat. In this paper, we review the bacterial etiologies
and the resistance patterns found in adults with serious UTIs and bacterial prostatitis, and discuss
considerations for selecting optimal antimicrobial therapy. The role of ﬂuoroquinolones as targeted
therapy for serious UTIs is highlighted. The use of effective antimicrobial therapy is the foundation of
management of serious UTIs and bacterial prostatitis. Selection of the optimal antimicrobial agent must
take into account patient-speciﬁc factors; infection characteristics (e.g., severity, community- vs.
institutional- or hospital-acquired, need for IV agent, UTI, prostatitis); local resistance pattern;
pharmacokinetic and pharmacodynamic principles; and cost. Fluoroquinolones are among the
alternatives for empirical antibiotic treatment of serious UTIs and acute bacterial prostatitis. In serious
UTIs activity of the antimicrobial agent against Pseudomonas aeruginosa needs to be taken into account. In
chronic bacterial prostatitis ﬂuoroquinolones are the ﬁrst choice because of their favourable pharma-
cokinetic properties at the site of infection.Targeted antimicrobial therapy – emphasising the correct
antibacterial spectrum and correct dosage – is likely to provide important beneﬁts, such as reduced
morbidity and associated costs, reduced emergence of resistance and maintenance of class efﬁcacy.
Keywords Bacterial prostatitis, complicated UTIs, ﬂuoroquinolones, hospital-acquired UTIs,
pharmacodynamics, resistance rates of uropathogens, review, targeted antimicrobial therapy
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INTRODUCTION
Urinary tract infections (UTIs) are among the
most prevalent microbial diseases, and their
ﬁnancial burden on society is substantial.
In the United States, UTIs are responsible for
over 7 million physician visits annually, including
more than 2 million visits for cystitis [1,2].
Approximately 15% of all community-prescribed
antibiotics in the United States are dispensed for
UTI, at an estimated annual cost of over $1 billion
[3]. Furthermore, the direct and indirect costs
associated with community-acquired UTIs in the
United States alone exceed an estimated $1.6
billion [2].
UTIs account for more than 100 000 hospital
admissions annually,most often for pyelonephritis
[1,2], and they also account for at least 40% of all
hospital-acquired infections and are in themajority
of catheter-associated cases [4–6]. Nosocomial bac-
teriuria develops in up to 25% of patients requiring
a urinary catheter for ‡ 7 days, with a daily risk of
5% [6]. It has been estimated that an episode of
nosocomial bacteriuria adds $500 to $1000 [7] to the
direct cost of acute-care hospitalisation. In addition
the pathogens are fully exposed to the nosocomial
environment, including selective pressure by anti-
biotic or antiseptic substances. Therefore nosoco-
mial UTIs comprise perhaps the largest
institutional reservoir of nosocomial antibiotic-
resistant pathogens [6].
Whereas community-acquired UTIs are often
uncomplicated, almost all nosocomial UTIs are
complicated infections. Complicated UTI is a very
heterogenous entity, with a common pattern of
the following complicating factors:
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Anatomical, structural or functional alterations
of the urinary tract (e.g., stents, urine transport
disturbances, instrumentation of the urinary
tract, stones, tumours, neurological disorders);
Impaired renal function, by parenchymal dis-
eases, or pre-, intra- or post-renal nephropa-
thies (e.g., acute, chronic renal insufﬁciencies,
heart insufﬁciency);
Accompanying diseases that impair the patients
immune status (e.g., diabetes mellitus, liver
insufﬁciency, immunosuppression, cancer,
AIDS, hypothermia).
For antimicrobial chemotherapy the bacterial
spectrum, its antimicrobial resistance patterns
and the development of both over time are critical
for effective chemotherapy.
The bacterial spectrum of complicated, nosoco-
mial UTI is heterogenous and comprises a wide
range of Gram-negative and Gram-positive spe-
cies. The bacterial spectrum can vary geograph-
ically, over time and among units even at the
same institution.
Table 1 shows the bacterial spectrum of
nosocomial UTI from four different studies:
North-America (SENTRY study), Europe (ES-
GNI-003 study), urological patients in Europe
(PEP-study), and hospitalised urological patients
in Straubing, Germany. In general, Gram-negative
species account for approximately 70–80% of the
spectrum and comprise Escherichia coli, followed
by Klebsiella spp., Pseudomonas spp., Proteus spp.,
Enterobacter spp. and Citrobacter spp. The Gram-
positive pathogens account for about 15–30% of
the spectrum and comprise enterococci, followed
by staphylococci [8–13].
The prostatitis syndrome is one of the most
common entities encountered in urologic practice.
Classiﬁcation of the prostatitis syndrome is based
on the clinical presentation of the patient, the
presence or absence of white blood cells in the
expressed prostatic secretion (EPS), and the pres-
ence or absence of bacteria in the EPS [14].
Depending on the duration of symptoms, prost-
atitis is described as either acute or, where symp-
toms are present for at least 3 months, chronic.
We refer to the classiﬁcation of the prostatitis
syndrome suggested by the National Institute of
Diabetes and Digestive and Kidney Diseases
(NIDDK) ⁄National Institutes of Health (NIH), in
which bacterial prostatitis (acute and chronic) is
distinguished from chronic pelvic pain syndrome
(CPPS) [15].
The Enterobacteriaceae, in particular E. coli, are
the predominant pathogens in bacterial prostatitis
Table 1. Bacterial spectrum of nosocomial uropathogens (‡ 2%) causing complicated UTIs, from distinct surveillance
studies
Name of study SENTRY [10] ESGNI-003 [11] PEP-study [13] Straubing [12]
Regions of the world North America Europe Europe Germany
Year of surveillance 1998 2000 2003 2001
Type of surveillance Longitudinal Cross-section Cross-section Longitudinal
Origin of samples Different
departments
in the hospital
Different
departments
in the hospital
Urology
departments
Urology
department
Number of pathogens (n) 1510 607 320 479
Species percentage
Escherichia coli 47% 36% 35% 41%
Klebsiella spp. 11% 8% 10% 7%
Pseudomonas spp. 8% 7% 13% 6%
Proteus spp. 5% 8% 7% 9%
Enterobacter spp. 4% 4% 3% 3%
Citrobacter spp. 3% 2% n.r. 3%
Enterococcus spp. 13% 16% 9% 18%
Staphylococcus spp. 6% 4% 4% 14%
Resistance rates of antibiotics
percentage
Ampicillin n.r. 66%a 51% 47%
Ampicillin + BLI n.r. 29%a 30% 30%
Trimethoprim ⁄ sulfamethoxazole n.r. 32%a 45% 22%
Ciproﬂoxacin 3–40%b 17%b 34% 24%
Gentamicin n.r. 18% 34% 28%
Ceftazidime 14%c 13%c 17% 28%
Amikacin 2%c 19%c 14% n.r.
Piperacillin ⁄Tazobactam 8%c n.r. 15% 8%
Imipenem 9%c 14%c 7% n.r.
Vancomycin 5%d 1%d n.r. 0%d
BLI, b-lactamase-inhibitors; n.r., not reported; aGram-negative bacteria excluding Pseudomonas aeruginosa; bGram-negative bacteria; cPseudonmonas aeruginosa; dEnterococcus
spp.
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(acute and chronic) [16], but to a lesser extent
other uropathogens are also found, e.g., Pseudo-
monas aeruginosa and enterococci. The signiﬁcance
of intracellular bacteria, such as Chlamydia tracho-
matis, Mycoplasmas and Ureaplasmas, is debatable.
In patients with systemic granulomatous infec-
tions or immune deﬁciencies, prostatitis may be
caused by fastidious pathogens such as Mycobac-
terium tuberculosis or Candida spp., or by rare
pathogens such as Coccidioides immitis, Blastomyces
dermatitidis and Histoplasma capsulatum [17].
Depending on the geographic region, otherwise
rarely cultured pathogens, e.g., Brucella spp., can
also play a role.
RESISTANCE OF UROPATHOGENS
It is well recognised that, over the last several
decades, antimicrobial resistance has evolved in
uropathogens responsible for complicated UTIs
and bacterial prostatitis.
Not unexpectedly, patients who experience a
complicated or hospital-acquired UTI are more
likely to harbour multiresistant pathogens than
patients with acute uncomplicated episodes. Part
of the explanation for this is that E. coli, a
traditionally highly susceptible organism, only
accounts for approximately half of infections in
patients with complicated or hospital-acquired
UTIs [18–20]. Moreover, recurrent E. coli infec-
tions are more likely to be caused by a highly
resistant strain [20]. The remaining plethora of
uropathogens acquired from patients with com-
plicated UTIs or from within institutions tends to
involve more difﬁcult-to-treat Gram-negative
bacilli and Gram-positive cocci.
ANTIBIOTIC RESISTANCE IN
COMPLICATED, NOSOCOMIALLY
ACQUIRED UTI
Nosocomial uropathogens are frequently subject
to antibiotic pressure and cross-infection. The
inﬂuence of these parameters can vary among
regions and medical specialities. Different species
of uropathogens show distinct abilities to elabor-
ate antibiotic resistance. Table 1 shows the resist-
ance rates of uropathogens in four surveillance
studies [10–13].
If the total bacterial spectrum is considered, the
aminopenicillins (with b-lactamase inhibitors)
showed resistance rates of approximately 60%
(respectively, 30%). Trimethoprim ⁄ sulfameth-
oxazole showed resistance rates between 22 and
45%. Resistance to ciproﬂoxacin was approxi-
mately 20–40%; to gentamicin 18–34%; to ceftaz-
idime 13–28%; to piperacillin ⁄ tazobactam 8–15%;
to imipenem 7–14%,; and resistance of entero-
cocci to vancomycin was between 0 and 5%.
In all the studies increasing resistance rates
were found with respect to speciﬁc species, e.g.,
E. coli, but not with all uropathogens. In partic-
ular, species e.g., P. aeruginosa, Klebsiella, Enterob-
acter, enterococci and coagulase negative
staphylococci became resistant to multiple antibi-
otic classes and substances. However, resistance
rates may vary substantially among regions.
Therefore local, hospital-based surveillance of
the bacterial spectrum and antibiotic sensitivity
is paramount for a rational empirical therapy.
Severe infections have lower mortality rates when
the empirical therapy has initially covered all
causative bacteria [21,22], which has been shown
for bacteremic UTIs as well [23].
Table 2 shows results from continuous surveil-
lance (1994–2004) of ciproﬂoxacin resistance in
uropathogens isolated from hospitalised urologi-
cal patients. Especially in E. coli, a steady increase
from 4% to approximately 12% was noted.
The activity of ﬂuoroquinolones against uro-
pathogens obtained from patients residing in
Germany with complicated or hospital-acquired
UTIs [24] is shown in Table 3. Speciﬁcally, the
MICs of ciproﬂoxacin, oﬂoxacin, trovaﬂoxacin,
gemiﬂoxacin, gatiﬂoxacin, and moxiﬂoxacin were
determined for 400 uropathogens. The most com-
monly isolated strains included E. coli and
enterococci, followed by P. aeruginosa, Proteus mir-
abilis, Klebsiella spp. and staphylococci. Although in
that study ﬂuoroquinolone resistance in uropath-
ogens was still low, the phenomenon of parallel
susceptibility and resistance with this antibiotic
class can be seen. In general, ciproﬂoxacin had the
lowest MIC values among the Gram-negative
pathogens, whereas gemiﬂoxacin had the lowest
MIC values among Gram-positive pathogens.
ANTIMICROBIAL TREATMENT
OPTIONS
General Considerations
The use of effective antimicrobial therapy is the
foundation of management of serious UTIs and
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bacterial prostatitis. Selection of the optimal anti-
microbial agent must take into account: patient-
speciﬁc factors (e.g., history of allergy, renal
function, concomitant medications); infection
characteristics (e.g., severity, community- vs.
institutional- or hospital-acquired, need for IV
agent); local resistance patterns; pharmacokinetic
and pharmacodynamic characteristics; and cost. It
is important to stress that culture and suscepti-
bility testing in patients with complicated UTIs
and bacterial prostatitis is not optional [25]. In
severe complicated UTI and ⁄ or pyelonephritis
and in acute bacterial prostatitis empirical ther-
apy has to be based on the local resistance pattern,
but treatment should be adapted according to
susceptibility testing. In mild to moderate com-
plicated UTI and in chronic bacterial prostatitis
antimicrobial therapy may not be initiated until
testing results are available. Patients with symp-
toms of chronic prostatitis must undergo some
form of quantitative segmental bacteriological
localisation cultures, such as the 4-glass test
described by Meares and Stamey or the 2-glass
test described by Nickel [26,27].
There are many intravenous and oral antimi-
crobial treatment options for patients with serious
UTIs (Table 4) [18,19,28–30]. Many patients with
serious episodes of complicated UTI or acute
prostatitis, includingmost hospital-acquired infec-
tions, require initial intravenous therapy because
of the possibility of bacteremia or sepsis, or
because of an impaired gastrointestinal tract
(e.g., vomiting) that does not permit reliable
absorption [28]. In addition, many experts agree
that empirical therapy for the institutionalised or
hospitalised patient with a serious UTI should
start with an intravenous antipseudomonal agent
[19,28]. Broadspectrum antimicrobial therapy
including antipseudomonal activity should be
considered for patients who have failed to respond
after several days of therapy with more narrow
spectrum agents (Table 4) [29,30]. For many years,
aminoglycoside therapy, with or without ampicil-
lin for enterococcal coverage, was a frequently
recommended option for patients with normal
renal function. The ability to prescribe all amino-
glycosides in once-daily doses has made this class
of compounds more attractive recently [31]. How-
ever, the risk of nephrotoxicity and ototoxicity
remains a concern with aminoglycoside therapy
and the need for routine serummonitoring increa-
ses the overall expense.T
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Numerous other parenteral options are
available for treatment of serious UTIs and
acute prostatitis, including extended-spectrum
b-lactams (b-lactam ⁄ b-lactamase inhibitor combi-
nations, imipenem, advanced-generation cephalo-
sporins) and ﬂuoroquinolones (Table 4). The
optimal agent should have adequate coverage
against P. aeruginosa, especially for intensive care
unit patients and for those with urosepsis. While
b-lactam antimicrobials are generally well-toler-
ated, care must be taken to avoid their use in
patients with a history of hypersensitivity.
Following deﬁnitive identiﬁcation of the caus-
ative pathogen and susceptibility testing, therapy
may need to be modiﬁed. The total duration of
therapy is longer for patients with complicated or
hospital-acquired UTIs (7–14 days) and patients
with bacterial prostatitis (acute 2–4 weeks,
chronic 4–6 weeks) compared with uncompli-
cated episodes (e.g., 3 days). Patients who
respond adequately to initial intravenous therapy
and who have a normally functioning gastroin-
testinal tract can be switched to oral therapy as
soon as possible.
Pharmacokinetic and pharmacodynamic
considerations in patients with complicated UTI
Adequate treatment of UTI depends on the
antimicrobial being able to inhibit the growth or
to kill bacteria present in the urinary tract.
Accordingly, antimicrobials that are primarily
Table 3. Minimal inhibitory concentrations (MICs, mg ⁄L) of ciproﬂoxacin, levoﬂoxacin, gatiﬂoxacin, gemiﬂoxacin and
moxiﬂoxacin
Pathogen n 0.008 0.016 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128
Escherichia coli
Ciproﬂoxacin 84 3 56 20 2 3
Levoﬂoxacin 84 4 53 22 2 3
Gatiﬂoxacin 84 35 41 5 3
Gemiﬂoxacin 70 25 42 1 1 1
Moxiﬂoxacin 84 4 48 29 3
Klebsiella spp.
Ciproﬂoxacin 13 1 4 4 3 1
Levoﬂoxacin 13 1 11 1
Gatiﬂoxacin 13 1 5 7
Gemiﬂoxacin 6 2 4
Moxiﬂoxacin 13 1 11 1
Proteus mirabilis
Ciproﬂoxacin 27 1 16 9 1
Levoﬂoxacin 27 1 14 11 1
Gatiﬂoxacin 27 1 3 19 4
Gemiﬂoxacin 27 1 10 16
Moxiﬂoxacin 27 2 2 20 3
Enterobacter spp.
Ciproﬂoxacin 6 1 2 2 1
Levoﬂoxacin 6 4 2
Gatiﬂoxacin 14 3 2 3 3 3
Gemiﬂoxacin 9 1 2 1 1 2 1 1
Moxiﬂoxacin 14 2 2 3 4 1 1 1
Pseudomonas aeruginosa
Ciproﬂoxacin 48 1 12 15 6 2 1 1 4 6
Levoﬂoxacin 48 2 22 7 5 1 2 9
Gatiﬂoxacin 48 17 11 5 4 5 6
Gemiﬂoxacin 45 12 16 6 2 1 8
Moxiﬂoxacin 48 5 20 8 4 10 1
Staphylococcus aureus
Ciproﬂoxacin 28 1 3 13 4 1 1 3 2
Levoﬂoxacin 28 4 14 4 1 3 2
Gatiﬂoxacin 28 1 11 6 4 1 5
Gemiﬂoxacin 27 5 10 3 2 1 1 3 2
Moxiﬂoxacin 28 3 10 7 2 1 5
CNS
Ciproﬂoxacin 57 2 21 5 5 1 3 3 5 12
Levoﬂoxacin 57 5 23 5 2 7 7 6 1 1
Gatiﬂoxacin 57 7 22 4 15 5 2 2
Gemiﬂoxacin 56 1 5 22 2 2 1 4 6 7 4 1 1
Moxiﬂoxacin 57 15 14 4 1 5 11 3 4
Enterococci
Ciproﬂoxacin 126 2 18 79 3 1 1 14 8
Levoﬂoxacin 126 1 1 12 85 4 1 6 12 4
Gatiﬂoxacin 126 5 73 24 1 1 8 14
Gemiﬂoxacin 125 4 57 40 5 11 8
Moxiﬂoxacin 126 2 31 69 1 5 11 7
CNS, coagulase-negative staphylococci.
Wagenlehner and Naber The treatment of complicated UTIs and prostatitis 71
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12 (Suppl. 3), 67–80
eliminated via renal excretion and achieve high
urinary concentrations (100–1000 times concomit-
ant serum concentrations) (e.g., ampicillin ⁄ sul-
bactam, cefuroxime, gatiﬂoxacin, levoﬂoxacin),
theoretically represent optimal choices for the
treatment of UTIs. But besides favourable phar-
macokinetics, an agent suitable for the treatment
of severe complicated UTI should also provide
optimal pharmacodynamic properties at the site
of infection, i.e., urinary bactericidal activity.
Thus, even for agents modestly eliminated by
renal mechanisms but with high intrinsic potency
(MIC) against the most common uropathogens
(e.g., ciproﬂoxacin), there are also important
considerations in antimicrobial selection [32].
Agents whose antibacterial activity are compro-
mised by changes in urinary pH may not be the
best choices for patients with serious UTIs. If
infection involves renal tissues or the patient has
urosepsis, antimicrobial concentrations must
exceed the MIC for the infecting pathogen to
produce the desired outcome. As such, adequate
serum concentrations are necessary to produce
high tissue concentrations, thereby necessitating
administration of high dose intravenous anti-
microbials.
While pharmacodynamic studies in UTI are
relatively scarce, at least one recent study has
documented that therapeutic success following
b-lactam therapy depends on the time the anti-
microbial concentration remains above the MIC
(T > MIC). A recent data analysis by Frimodt-
Møller reported that there was a signiﬁcant cor-
relation between the cumulative T >MIC and
bacteriological cure, wherein a cumulative T
>MIC of 30% or more of the 24 h dosage provided
a maximal cure rate of 80–90% [33]. The authors
postulated that the reason b-lactams often have not
provided successful outcomes in the treatment of
UTIs, comparedwith other antimicrobial classes, is
most likely improper dosing (i.e., dose too low and
infrequent dosage interval).
For drugs with concentration dependent time-
kill activity, such as the aminoglycosides and the
ﬂuoroquinolones, a positive outcome appears to
be more dependent on the Cmax ⁄MIC or AUC ⁄
MIC ratio. While it remains unclear which ratio is
a better predictor of outcome, in either case a high
ratio is desirable. The pharmacodynamics of
ciproﬂoxacin were investigated in one animal
model UTI study in mice infected with E. coli [33].
While data were limited to three points, there was
an obvious correlation between reduced bacterial
counts and the AUC ⁄MIC ratio. Despite the
paucity of pharmacodynamic data to guide ther-
apy of UTIs, it has been noted that among the
available quinolones, the Cmax ⁄MIC and AUC ⁄
MIC ratios are highest for ciproﬂoxacin against
Table 4. Recommendations for the empirical antibiotic therapy of UTI (modiﬁed from Naber et al., 2001 [30])
Diagnosis Frequent uropathogens Empirical initial therapy Duration of therapy
UTI Escherichia coli Fluoroquinolone At least 3–5 days after
defervescence, respectively,
removal of the complicating
factor
Complicated
nosocomial UTI
Enterococci Aminopenicillin ⁄BLI
Pyelonephritis acute,
complicated
Pseudomonas spp. Cefotaxime, ceftriaxone
Staphylococci Ertapenem 2–3 days after defervescence
in patients with indwelling
catheters
Klebsiella spp. If initial therapy fails
after 1–2 days:
Proteus spp. Piperacillin ⁄ tazobactam
Enterobacter spp. Ceftazidime, cefepime
other Enterobacteria
(Candida spp.)
Imipenem, meropenem
In case of Candida spp.:
Fluconazole Voriconazole
Caspofungin Amphotericin B
Prostatitis-acute Escherichia coli Ciproﬂoxacin, levoﬂoxacin,
gatiﬂoxacina, moxiﬂoxacina
2–4 weeks
Enterococci Aminopenicillin ⁄BLI
Pseudomonas spp. Cefotaxime, ceftriaxone
Staphylococci Ertapenem
Klebsiella spp. If initial therapy fails after 1–2 days:
Proteus spp. Piperacillin ⁄ tazobactam
Enterobacter spp. Ceftazidime, cefepime
other Enterobacteria Imipenem, meropenem
Prostatitis chronic, bacterial Ciproﬂoxacin, levoﬂoxacin,
gatiﬂoxacina, moxiﬂoxacina
4–6 weeks
BLI, b-lactamase inhibitor.
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P. aeruginosa [34]. For other Gram-negative infec-
tions, the pharmacodynamic properties are more
similar among the available quinolone agents.
This model was unable to evaluate the aminogly-
cosides using pharmacodynamic principles be-
cause these agents are characterised by high
binding to the renal cortex [33].
Severe UTIs, however, are a combination of
tissue infection and urine infection. A signiﬁcant
part of the bacteria (sometimes more than 106 ⁄mL)
is found free in the bladder lumen. Therefore a high
urinary excretion of the antibiotic is also needed.
The urinary concentration, however, has to be
correlated with the respective antibacterial activit-
ies. This can be done, for example, in an ex-vivo
model by determining the urinary bactericidal
titres (UBT). In this model pharmacokinetic and
pharmacodynamic parameters of an antibiotic in
urine are linked together. Various ﬂuoroquinolo-
nes have been compared with each other in this
way, showing that theurinary concentrations (after
an oral single dose of 500 mg ciproﬂoxacin, 400 mg
enoxacin and 400 mg norﬂoxacin) were highest
with enoxacin, followed by ciproﬂoxacin and
norﬂoxacin. The determination of theUBTs against
susceptible Gram-positve and -negative uropatho-
gens, however, showed that the activity of ciproﬂ-
oxacin was twice that of enoxacin and twice that of
norﬂoxacin [32]. Therefore, one dose of ciproﬂoxa-
cin is comparable to two doses of enoxacin or four
doses of norﬂoxacin, in order to achieve compar-
able UBTs. In similar investigations ciproﬂoxacin
was compared with levoﬂoxacin and gatiﬂoxacin
[35]. If these results are summarised and compared
with the data of clinical studies, equivalent dosages
for oral ﬂuoroquinolones can be detemined.
Appropriate dosing is especially important to
minimise the development of resistance and to
maintain antimicrobial efﬁcacy. For patients with
serious UTIs, higher than approved doses may be
needed, especially against difﬁcult-to-treat path-
ogens such as P. aeruginosa [32]. For example,
intravenous or oral ciproﬂoxacin 750 mg twice-
daily or levoﬂoxacin 500 mg twice-daily may be
more appropriate than conventional dosing.
Pharmacokinetic and pharmacodynamic
considerations in patients with acute or chronic
prostatitis
The drug penetration in the prostate tissue is
supposedly a passive transport mechanism invol-
ving of diffusion and concentration [36]. The drug
characteristics that determine simple diffusion are
concentration, lipid solubility, degree of ionisa-
tion (biological membranes do not allow the
passage of charged substances), degree of protein
binding, and the size and shape of the molecule
(small water-soluble molecules can cross biologi-
cal membranes as part of the free water diffusion).
The presence of a pH gradient across a biological
membrane introduces the phenomenon of ion
trapping. In a stable system the uncharged frac-
tion of a lipid-soluble drug equilibrates on the
two sides of the membrane, but the charged
fraction is greater on one side or the other,
depending on the pH. The greatest drug concen-
tration (sum of charged and uncharged fractions)
is on the side with the higher degree of ionisation.
Thus, a weak base, as in trimethoprim with a pKa
of 7.4, will be concentrated in an acidic prostatic
ﬂuid as found in dogs [37], but not in an alkaline
mileu, such as seminal ﬂuid. The pH of prostatic
ﬂuid in patients with chronic bacterial prostatitis
is also often alkaline; thus concentrations in
prostatic secretion may be inadequate [38,39].
The ﬂuoroquinolones in clinical use are neither
pure acids nor bases but have characteristics of
both, i.e., amphoteric or zwitter-ionic drugs
[40,41]. Most quinolones that are amphoteric
drugs have two ionising groups, one positively
and one negatively charged, and thus two pKa
values [41]. At one pH value, which is between the
two pKa values and is different for each ampho-
teric drug, the amount of charged drug is minimal
(isoelectric point). At higher and lower pH values
more drug is charged. Since the highest drug
concentration occurs on the side with the higher
degree of ionisation, drugs with an isoelectric
point close to plasma pH should concentrate in
ﬂuids with a pH above and below plasma pH. This
allows prostatic ﬂuid levels that compare favour-
ably with plasma levels, with ratios ranging from
0.12 to 1.02 (Table 5) [42–45]. The concentration of
some ﬂuoroquinolones in the alkaline seminal
ﬂuid may even exceed that in plasma (Table 5).
Macrolides also penetrate into prostatic and
seminal ﬂuids very well [36,46]. Although it
remains unproven clinically, considerable evi-
dence suggests that bacteria in prostatic tissue
survive in a milieu protected by bioﬁlms [47].
The reason for the administration of antibiotics
for chronic pelvic pain syndrome (CPPS) with
inﬂammation (NIH category IIIA), in which no
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pathogens can actually be cultured, is that there
may be a bacterial infection even though bacteria
are not detected by conventional methods. How-
ever, by using a 16S rDNA assay, bacterial DNA
sequences could be detected in a high rate in
patients with CPPS [48]. Furthermore, clinical
studies report the positive effects of antibiotics in
inﬂammatory CPPS [49,50]. Antimicrobial ther-
apy ex juvantibus is therefore justiﬁed. An oral
ﬂuoroquinolone should be given for 2–4 weeks
after the initial diagnosis. The patient should be
reassessed and antibiotics continued only if the
patient reports a positive effect of the treatment in
terms of pain relief. A total treatment period of 4–
6 weeks is then recommended [51]. Table 6 shows
a possible algorithm for the treatment of prosta-
titis syndrome.
FLUOROQUINOLONE CLINICAL
STUDIES IN PATIENTS WITH
COMPLICATED UTI
A limited number of US and international clinical
trials have been published, and provide
evidence to support the effectiveness of the
ﬂuoroquinolones in the treatment of complicated
and hospital-acquired UTIs [52–75]. However, the
ﬁndings of these trials are often difﬁcult to
compare or interpret because of differing or
incomplete deﬁnitions of the ‘complicated’ aspect.
Although these trials vary in their study design,
many support the use of ﬂuoroquinolones in the
treatment of serious or complicated UTIs; the
most experience has been garnered with ciproﬂ-
oxacin [52–64]. Several contemporary and key
ciproﬂoxacin studies are described in more detail
below.
The majority of the published ciproﬂoxacin
trials on serious UTI employed the conventional
twice-daily tablet [52,57–63], while one recent
preliminary report demonstrated the effectiveness
of a new once-daily extended-release tablet for-
mulation [64]. Three of these studies were con-
ducted primarily in Germany and used a
relatively low dose of ciproﬂoxacin (250 mg twice
a day), but with good outcomes [60–62]. The
majority of these published clinical trials with oral
ciproﬂoxacin reveal excellent bacteriologic
(> 84%) and clinical cure rates (> 90%). As
expected, all of these trials demonstrated that
Table 5. Concentrations of ﬂuoroquinolones in prostatic and seminal ﬂuids (in case of split ejaculation, portion 2) of
volunteers 2–4 h after drug administration [42–45]
Concentrations of Fluoroquinolones in Prostatic and Seminal Fluids
Quinolone
Dose
(mg)
Median
plasma
concentration
(mg ⁄L)
Median
prostatic ﬂuid
concentration
(mg ⁄L)
Median ratio of
prostatic ⁄plasma
drug concentrations
Median seminal
ﬂuid concentration
(mg ⁄L)
Median ratio
of seminal ⁄plasma
drug concentrations
Norﬂoxacin 800 PO 1.40 0.14 0.12 n.d. –
Ciproﬂoxacin 200 IV 0.44 0.08 0.18 2.53 7.1
750 PO 0.88 0.23 0.23 6.57 7.7
Fleroxacin 400 PO 3.71 1.00 0.28 5.80 1.7
Oﬂoxacin 400 PO 2.00 0.66 0.33 4.09 4.0
Enoxacin 400 PO 1.09 0.39 0.39 2.19 2.2
428 IV 1.26 0.57 0.47 3.50 2.8
Lomeﬂoxacin 400 PO 1.81 1.38 0.48 2.04 1.3
Gatiﬂoxacin 400 PO 1.92 1.03 1.02 1.75 1.0
n.d., not done.
Table 6. Practical recommendations for antibiotic therapy in prostatitis
Acute bacterial prostatitis-NIH category I
Quantitative segmental bacteriological localisation cultures and microscopy of EPS
not indicated. Isolation of pathogen from urine.
(1) Empirical therapy with b-lactam antibiotics and ⁄ or ﬂuoroquinolones After
susceptibility testing adaptation of therapy, if needed. After clinical improvement
continued antibiotic oral therapy for 4–6 weeks.
(2) In case of residual urine: < 100 mL, add a-receptor blocker > 100 mL, insert
suprapubic catheter (3) In case of prostatic abscess, surgical therapy (e.g., TURP)
Chronic bacterial prostatitis-NIH category II
Quantitative segmental bacteriological localisation cultures and microsco-
py of EPS mandatory.
(1) Empirical therapy with ﬂuoroquinolones (4–8 weeks) ± a-receptor
blocker (6 months)
(2) In case of recurrent infection or reinfection repeated bacteriological
sampling and widended diagnostics (e.g., urodynamics), adaptation of
antibiotic therapy if needed.
Inﬂammatory CPPS-NIH category III A
Quantitative segmental bacteriological localisation cultures and microscopy of EPS
mandatory.
(1) Oral ﬂuoroquinolone for 2–4 weeks.
(2) Reassessment of patient and continuation of antibiotics only if patient reports
clinical improvement. A total treatment period of 4–6 weeks is then recommended.
Non inﬂammatory CPPS-NIH category III B ⁄ Asymptomatic prostatitis-
NIH category IV
Quantitative segmental bacteriological localisation cultures and microsco-
py of EPS mandatory No consensus regarding the role of antibiotic
treatment.
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ciproﬂoxacin was at least equivalent to a compa-
rator regimen (e.g., oﬂoxacin, gatiﬂoxacin). In
general, ciproﬂoxacin was effective for serious
UTIs due to P. aeruginosa.
One study demonstrated that ciproﬂoxacin was
signiﬁcantly bacteriologically superior to a com-
parator agent in a population with long-term
bladder catheterisation [52]. The bacteriologic
response at the early follow-up visit (5–9 days
post-therapy) demonstrated that ciproﬂoxacin
500 mg twice daily was superior to the amino-
glycoside regimen (p ¼ 0.0005) [52]. The
response rates were similar between the two
treatment groups at the long-term follow-up visit
(28–30 days post-therapy). In this trial, 75% of
P. aeruginosa isolates were eradicated at the short-
term follow-up by both ciproﬂoxacin and amino-
glycoside regimens, although there was a high
rate of recurrence in both treatment groups. While
ciproﬂoxacin provided superior short-term re-
sults, recurrence was high in both treatment
groups, probably due to the presence of bioﬁlms
and the fact that catheters could not be removed
in these patients. These ﬁndings stress the difﬁ-
culty in treating patients who have permanent
indwelling urinary catheters.
We evaluated the efﬁcacy of two oral dosing
regimens of gatiﬂoxacin compared with ciproﬂ-
oxacin in the treatment of complicatedurinary tract
infection in a randomised, double-blind multicen-
tre trial [63]. One thousand one hundred and
twenty-three adult patients with complicated UTI
(70%) or pyelonephritis (30%) were initially en-
rolled, and 1122 were treated. Of these, 824 were
included in a modiﬁed intent-to-treat (ITT) popu-
lation: gatiﬂoxacin 200 mg (274 patients) or 400 mg
(280 patients) once daily or ciproﬂoxacin 500 mg
twice daily for 5–14 days (269 patients). Bacterio-
logical and clinical responses were assessed
7–9 days after the end of treatment (EOT) and
4–6 weeks post-treatment (end-of-study visit,
EOS). The bacteriological response rates per
patient at EOT in the gatiﬂoxacin 400 mg, gatiﬂ-
oxacin 200 mgand ciproﬂoxacin groupswere 77%,
78% and 73%, respectively. At EOS they were
slightly lower: 70%, 71% and 69%, respectively.
The clinical responses at EOT were 69%, 70% and
65%, respectively.AtEOS theywere 71%, 70% and
74%, respectively. The overall eradication rates of
initial pathogens at EOT and EOS were 85.3% and
88.4%, respectively in the gatiﬂoxacin 400 mg
group; 84.1 and 90.1%, respectively in the gatiﬂ-
oxacin 200 mg group and 85.1 and 91.4%, respec-
tively in the ciproﬂoxacin group. Therefore both
oral regimens of gatiﬂoxacin were as effective as
that of ciproﬂoxacin.
A recent large, North American study was
completed by Talan et al. wherein extended-
release ciproﬂoxacin (1000 mg once daily) was
compared with standard twice-daily ciproﬂoxacin
500 mg, each for 7–14 days duration for patients
with complicated UTIs [64]. Of 1035 intent-to-
treat patients, including some patients with acute
uncomplicated pyelonephritis, a valid pretherapy
pathogen was isolated in 641 patients. The MIC90s
for the most frequently isolated Gram-negative
pathogens were: E. coli (0.25 mg ⁄L), K. pneumoniae
(0.5 mg ⁄L), and Proteus mirabilis (2.0 mg ⁄L).
Overall, 49 of 1035 (4.7%) patients had ciproﬂ-
oxacin-resistant (MIC ‡ 4 mg ⁄L) uropathogens at
baseline. Only patients with ciproﬂoxacin-sus-
ceptible isolates were subsequently evaluated
for efﬁcacy. At the test-of-cure visit (5–11 days
post-therapy), bacteriologic eradication in the
complicated UTI cohort was achieved in 89% of
extended-release ciproﬂoxacin recipients vs. 81%
of twice-daily ciproﬂoxacin recipients. Corres-
ponding rates of clinical success were 96% and
93%, respectively. Long-term success rates were
comparable between the treatment groups. The
authors concluded that extended-release once-
daily ciproﬂoxacin 1000 mg was as effective as
standard twice-daily ciproﬂoxacin 500 mg in
adults with complicated UTI.
Mombelli et al. investigated the efﬁcacy of oral
(500 mg twice daily) vs. intravenous ciproﬂoxacin
(200 mg twice a day) as empirical therapy in 141
patients with community- and hospital-acquired
complicated UTIs or severe pyelonephritis [56].
Only patients with severe sepsis (deﬁned as the
presence of infection-related organ dysfunction)
were excluded. Resistance to ciproﬂoxacin was
found for 11 (8%) baseline organisms, including
ﬁve enterococcus spp. and one each of P. aerugi-
nosa, E. coli, Enterobacter spp., Staphylococcus aure-
us, coagulase negative staphyloccci, and Candida
albicans. This study found that empirical oral
ciproﬂoxacin was bacteriologically and clinically
as effective as intravenous ciproﬂoxacin for man-
agement of serious UTIs, including bacteremia, in
patients without severe sepsis, obstruction, or
renal foci of suppuration. Rates of bacteriologic
failure or unsatisfactory clinical response were
extremely low (2% and 3%, respectively, for
Wagenlehner and Naber The treatment of complicated UTIs and prostatitis 75
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12 (Suppl. 3), 67–80
intravenous regimes vs. 3% and 4% for oral
regimes). Importantly, no infection-related deaths
occurred and no patient had to be switched from
empirical to alternative therapy early because of
clinical worsening. However, treatment was ulti-
mately altered following availability of suscepti-
bility ﬁndings in 7% of those randomised to
intravenous ciproﬂoxacin vs. 14% of oral ciproﬂ-
oxacin recipients (p ¼ 0.31). There are several
unique aspects and ﬁndings to this trial: enrolled
patients had serious UTIs, including 53 patients
with proven bacteremia; males comprised over
40% of the study population and nosocomial
acquisition was reported for 23%; and patients
with resistant organisms were not automatically
excluded. It is also noteworthy that the majority
of ciproﬂoxacin resistance was against Gram-
positive organisms and that despite this, most
patients had an adequate initial clinical and
bacteriologic response. In fact, clinical response
to ciproﬂoxacin was satisfactory in six of seven
patients with ciproﬂoxacin-resistant pathogens,
including two with episodes of bacteraemia.
Although this study was not large, it provides
compelling evidence that both intravenous and
oral ciproﬂoxacin are effective in the initial
treatment of patients with serious UTIs, including
nosocomially acquired infections.
FLUOROQUINOLONE CLINICAL
STUDIES IN PATIENTS WITH
CHRONIC BACTERIAL PROSTATITIS
Most studies in patients with chronic bacterial
prostatitis (CBP) have not been well controlled
and have been variably designed [44,76]. As a
result, comparison is difﬁcult. Duration of ther-
apy has ranged from 14 to 150 days and follow-
up investigation has not been standardised. Since
relapse and reinfection are commonly observed in
these patients, only the results of studies with a
follow-up of at least 6 months should be taken
into consideration. In this respect most experience
has been gathered with ciproﬂoxacin [77–85].
Overall, it appears that 60–80% of patients with
E. coli and other Enterobacteriaceae can be cured
with a 4–6-week course of therapy. However,
prostatitis due to P. aeruginosa and enterococci
often fails to respond to treatment. Newer ﬂuor-
oquinolones, such as levoﬂoxacin or gatiﬂoxacin,
with improved activity against Gram-positive and
so-called atypical pathogens, have not yet been
tested sufﬁciently in suitable clinical trials [76,86].
One trial tested levoﬂoxacin 500 mg (once daily)
vs. ciproﬂoxacin 500 mg (twice daily) with a two-
week follow-up and reported similar clinical
success rates of 75% and 73%, respectively, and
similar microbiologic eradication rates of 75%
and 77%, respectively [87].
CURRENT APPROACH TO
TREATMENT
SeriousUTI and acute bacterial prostatitis episodes
require immediate empirical treatment, and often
hospitalisation and administration of intravenous
antimicrobials, especially in the case of severe
presentations (e.g., fever, vomiting) or when uro-
sepsis is suspected. In patients with chronic bac-
terial prostatitis the choice of antibiotic therapy
should await identiﬁcation and susceptibility
results. The pathogens encountered in patients
with serious UTIs and acute prostatitis are unpre-
dictable, and include non-E. coli Gram-negative
bacteria and, to a lesser extent, Gram-positive
bacteria (approximately 20%), and have a high
potential for being drug-resistant [10]. Accord-
ingly, an appropriately collected urine specimen
must be obtained for culture and susceptibility
testing for each serious UTI episode prior to
initiating therapy. Selection of empirical antibiotic
therapy must take into account current resistance
patterns for common uropathogens and be indi-
vidualised for a given facility, hospital ward, and
community, as well as individual patient factors
based on prior therapy and underlying comorbi-
dities. Because many patients often have underly-
ing immunosuppression (e.g., advanced age,
comorbidities), potent broad-spectrum coverage
directed primarily at Gram-negatives, including P.
aeruginosa, may be needed [19,20]. The decision to
initiate empirical therapy with an antipseudomo-
nal agent remainsone of clinical judgment, butmay
become necessary following identiﬁcation of P.
aeruginosa from an appropriately cultured urine
specimen. Uropathogens causing chronic bacterial
prostatitis frequently are antibiotic resistant, be-
cause patients with recurrent infections typically
have undergone multiple antibiotic treatment reg-
imens.
The selection of an optimal empirical therapy for
treatment of serious UTI and acute bacterial prost-
atitis remains challenging formany physicians and
will depend mostly on the expected bacterial
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spectrum, its susceptibility proﬁle and suitable
pharmacokinetic ⁄pharmacodynamic properties
[30]. While a number of antimicrobials are indica-
ted for treatment of complicated UTIs, the need to
cover a range of Gram-negative andGram-positive
bacteria with unpredictable susceptibility patterns
often confounds the therapeutic selection process.
Over the last two decades, extended-spectrum b-
lactam antimicrobials have showndecreased activ-
ity against common nosocomial urinary tract path-
ogens [10]. Furthermore, many b-lactams also lack
reliable antipseudomonal coverage, making these
less attractive monotherapeutic options. Fluoroqu-
inolones provide excellent Gram-negative cover-
age, but with varied activity against P. aeruginosa
and Gram-positive strains. Ciproﬂoxacin remains
the most potent ﬂuoroquinolone in vitro against P.
aeruginosa [24,88], although resistance has risen in
the two decades of its use [8,10]. For hospitalised
patients with suspected pseudomonal infection,
ciproﬂoxacin is the most logical empirical choice
when susceptibility patterns for the institution
warrant its use. For patientswithout risk factors for
pseudomonal infection, other intravenous and oral
ﬂuoroquinolones, such as levoﬂoxacin and gatiﬂ-
oxacin, are options. For patients who can be
switched to oral therapy (e.g., those with a positive
response following intravenous therapy and ade-
quate gastrointestinal function), extended-release
once-daily ciproﬂoxacin is an effective new option,
although there are limited data concerning
P. aeruginosa [64]. Regardless of the agent chosen,
treatment of serious UTIs is typically prolonged
(7–14 days) in order to ensure microbiological
success and a low rate of clinical relapse
[28,89,90]. Correcting the underlying urinary tract
abnormalities responsible for the infection is also
crucial to management of patients with complica-
ted UTIs.
Treatment of acute bacterial prostatitis should
last for 2–4 weeks to prevent development of
chronic bacterial prostatitis [51]. Fluoroquinolones
are the ﬁrst choice of agents because of their
favourable pharmacokinetics in the prostate tissue
and prostatic excretions. All other antibiotic clas-
ses available (except macrolides) exhibit inferior
pharmacokinetic properties in that respect [51].
CONCLUSION
Physicians have an increasing responsibility to
select the most appropriate antimicrobial for
treatment of all infections, including serious UTIs
and bacterial prostatitis. The use of targeted
therapy ) emphasising the antibacterial spectrum
and pharmacodynamic properties ) is likely to
provide important beneﬁts, such as reduced
morbidity and associated costs, reduced emer-
gence of resistance and maintenance of class
efﬁcacy [34]. While many antimicrobial agents
may be clinically effective against UTIs, the use of
agents with only marginal activity against given
pathogens may compromise the effectiveness of
other agents in the same class and in some cases,
reduce the usefulness of agents in other classes.
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